



ASEAN-Focused CDMO Landscape

WHY CDMO PARTNERSHIPS POWER ASEAN BIOLOGICS

Growing demand for monoclonal antibodies (mAbs), biosimilars, antibody-drug conjugates (ADCs) and next-generation biologics is driving partnerships between global manufacturing leaders and regional biopharma companies.

For ASEAN markets, CDMO partnerships unlock four core advantages that accelerate the journey from early research to commercial supply.



Faster development timelines

Supporting biotech companies from early research through clinical and commercial manufacturing.



Advanced manufacturing capabilities

Including cell culture, process development, GMP production, analytical services and scale-up expertise.



Regional manufacturing resilience

Helping Southeast Asia expand local production capacity and reduce dependence on overseas supply chains.



Technology transfer & knowledge sharing

Supporting the development of sustainable biologics ecosystems across the region.

CDMO LANDSCAPE SERVING SOUTHEAST ASIA

DIRECTORY

Leading contract development & manufacturing organisations with a Southeast Asia footprint.

Lonza
Specialized Modalities

Lonza

♦ SINGAPORE

mAbs, mammalian cell culture, biologics manufacturing, cell & gene therapy

WuXi Biologics
Global Solution Provider

WuXi Biologics

♦ SINGAPORE

End-to-end biologics CDMO, cell line development, process development, GMP manufacturing

**SAMSUNG
BIOLOGICS**

Samsung Biologics

♦ APAC

Large-scale biologics manufacturing, mAbs, biosimilars, ADC-related capabilities

**ThermoFisher
SCIENTIFIC**

Thermo Fisher Scientific

♦ SINGAPORE

Biologics development, clinical & commercial manufacturing (Patheon)

CDMO LANDSCAPE SERVING SOUTHEAST ASIA

DIRECTORY

Leading contract development & manufacturing organisations with a Southeast Asia footprint.



Boehringer Ingelheim

♦ GLOBAL / APAC

Commercial biologics, mammalian manufacturing, mAbs (BioXcellence)



AGC Biologics

♦ ASIA

Mammalian & microbial biologics, mRNA, viral vectors, plasmid DNA



Esco Aster

♦ SINGAPORE

CRDMO services, cell & gene therapy, viral vectors, GMP manufacturing



GenScript

♦ SINGAPORE

Protein engineering, gene synthesis, biologics development platforms

WHY CDMOS MATTER TO SEA'S BIOLOGICS FUTURE

The growth of ASEAN's biologics sector depends on tight collaboration across the value chain — from innovators to the healthcare systems that ultimately deliver therapies to patients.



Together, these stakeholders are building the foundation for a competitive regional biologics ecosystem.

CONNECT WITH BIOLOGICS LEADERS

Biologics World Southeast Asia 2026 unites global CDMOs, biotech companies, manufacturers, regulators and technology providers — including the leaders featured below — to shape the future of biologics development and manufacturing in ASEAN.



KEY DISCUSSIONS INCLUDE



CDMO partnerships & technology transfer



Scaling biomanufacturing capacity



Bioprocessing innovation



Advanced biologics platforms



Clinical development & commercialisation

14-15 October 2026



Sheraton Grand Jakarta Gandaria City Hotel
Jakarta, Indonesia

Join the region's leading platform
shaping Southeast Asia's next era of
biologics innovation.